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Abstract
Experimental evidence supports a pathogenic role of free radicals or reactive oxygen
species (ROS) in the mechanism of hypertension. Indeed, vascular ROS produced in a
controlled manner are considered important physiological mediators, functioning as
signaling molecules to maintain vascular integrity by regulating endothelial function
and vascular contraction‐relaxation. However, oxidative stress can be involved in the
occurrence of endothelial dysfunction and related vascular injury. Thus, ROS activity
could  trigger  pathophysiological  cascades  leading  to  inflammation,  monocyte
migration, lipid peroxidation, and increased deposition of extracellular matrix in the
vascular wall, among other events. In addition, impairment of the antioxidant capacity
associates with blood pressure elevation, indicating potential role of antioxidants as
therapeutic antihypertensive agents. Nevertheless, although increased ROS biomark‐
ers have been reported in patients with essential hypertension, the involvement of
oxidative stress as a causative factor of human essential hypertension remains to be
established. The aim of this chapter is to provide a novel insight into the mechanism of
essential hypertension, including a paradigm based on the role played by oxidative
stress.
Keywords: essential hypertension, oxidative stress, antioxidants, endothelial dysfunc‐
tion, nitric oxide
1. Introduction
Hypertension is a major risk factor for cardiovascular disease [1]. Recently, a growing body
of evidence has involved oxidative stress in the mechanism of development of hyperten‐
sion. Indeed, reactive oxygen species (ROS) contribute to regulating the biological processes
occurring in the vascular wall, both in normal physiological conditions, as well as in the
occurrence of hypertension [2–4]. Available evidence of the contribution of oxidative stress in
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the pathogenesis of human hypertension includes enhancement of ROS production, togeth‐
er  with  decreased  bioavailability  of  both  nitric  oxide  (NO)  and  antioxidants.  The  first‐
formed ROS is superoxide anion radical, which is produced from NADPH oxidase (NOX), an
enzyme subjected to regulation by hormones such as angiotensin II (AT‐II), endothelin‐1 (ET‐
1), and urotensin II (UT‐II), among others. Furthermore, mechanical stimuli known to occur
in blood pressure elevation further contribute to increased ROS production. It is of interest to
mention that increased intracellular calcium concentration may result from ROS‐induced
vasoconstriction,  thus enhancing the development of  hypertension [2].  The regulation of
vasomotor tone depends upon a delicate balance between vasoconstrictor and vasodilator
forces, the latter being likely to be modulated by oxidative stress. This view has stimulated
the interest for searching novel antihypertensive therapies aimed to decrease ROS genera‐
tion and/or increase NO bioavailability. The present study was aimed to present an update of
the available studies related to the role of oxidative stress in the mechanism of development
of blood pressure elevation, as well as the role of antioxidants in the prevention or treat‐
ment of this derangement.
2. Pathophysiology of hypertension
2.1. Endothelial dysfunction
The response to cardiovascular risk factors is expressed in alterations of endothelial function,
a chronic inflammatory process characterized by loss of antithrombotic factors and an increase
in vasoconstrictor and prothrombotic products, thus elevating the risk of cardiovascular
events. Consequently, an impairment of the ability of endothelium to induce vasodilation leads
to hypertension. Recently, it has been argued that ROS play a key role in this pathological
process.
2.2. Role of vascular oxidative stress in hypertension
The occurrence of oxidative stress is due to an imbalance between ROS generation and the
antioxidant potential in the body, the latter being overwhelmed by the increased ROS con‐
centration in the steady state. It should be noted that although ROS are mediators of normal
biological effects related to vascular function at the cell level, the increased levels of these
species can give rise to pathological changes, as those observed in cardiovascular disease. ROS
behave as redox‐sensitive blood pressure modulators [5–7]. Accordingly, increased ROS
concentration has been demonstrated both in patients with essential hypertension and in
various animal models of hypertension [8–12]. In addition, this derangement is accompanied
by a decreased antioxidant potential [13]. Therefore, these data provide evidence of the
involvement of vascular oxidative stress in the mechanism of development of essential
hypertension [2, 3, 14]. Furthermore, a strong association between blood pressure and
oxidative stress‐related parameters has been found, such as plasma 8‐isoprostane levels [15].
Interestingly, studies performed in mice models having genetic deficiency in ROS‐generating
enzymes showed that these animals had lower blood pressure than control with wild‐type
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mice [16, 17]. Moreover, at the cellular level, it has been reported that ROS production is
enhanced in cultured vascular smooth muscle cells (VSMC) isolated from both hypertensive
rats and isolated arteries of hypertensive human patients; these findings are associated with
amplified, redox‐dependent signaling and reduced antioxidant bioactivity [18]. These reports
could support the view that the modulation of oxidative stress could be expressed in blood
pressure lowering in the case of known antihypertensive agents, such as β‐adrenergic blockers,
angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor antagonists, and
calcium channel blockers [19, 20].
2.2.1. Vascular ROS sources
There are various ROS sources formed in blood vessels, from both enzymatic and non‐
enzymatic origin. Together with the mitochondrion, the major enzymatic sources comprise
NADPH oxidase (NOX), xanthine oxidase (XO), and uncoupled NO synthase.
2.2.1.1. NADPH oxidase
In the vascular wall, as well as in the kidney, superoxide anion is mainly produced enzymat‐
ically through NOX activity; consequently, the upregulation of this enzyme exerts an impor‐
tant pathogenic role in the development of renal dysfunction and vascular damage [12, 21].
The enhanced activity of NOX in hypertension is achieved through mechanical and humoral
signals, with AT‐II being the most studied stimulus. However, it is important to remark that
ET‐1 and UT‐II cooperatively participate in NOX activation. In addition, NOX‐derived
superoxide anion is able to inactivate NO, thus producing peroxynitrite anion. The latter
induces downregulation of prostacyclin synthase, further allowing the development of
hypertension. Finally, oxidative stress leads to eNOS uncoupling [16, 22]. Therefore, several
effects contribute to the impairment of endothelial function related to oxidative stress. In
summary, increased superoxide anion, decreased NO bioavailability, and decreased prosta‐
cyclin synthesis contribute to the impairment of endothelium‐dependent vasodilation. Thus,
NOX activation in the vascular wall results in several effects contributing to the mechanism
of development of hypertension [23].
2.2.1.2. Uncoupled endothelial NO synthase
The vascular tone is modulated by vasoconstriction‐vasodilation balance, and NO bioavaila‐
bility constitutes an important component of the latter process. The NO production is partly
dependent upon the activity of eNOS. However, other factors, such as L‐arginine and tetra‐
hydrobiopterin (BH4) availability, are also required as substrate and coupling factor, respec‐
tively. Deficiency or oxidation of either of these two factors will result in decreased NO
production. The initial ROS source is NOX‐dependent superoxide generation. Furthermore,
peroxynitrite is formed through the reaction between NO and superoxide [24]. The activity
and function of eNOS are changed due to the peroxidant ability generated by peroxynitrite,
and this enzyme produces more superoxide instead of NO [22, 25]. This vicious cycle results
in BH4 oxidation, thereby promoting eNOS uncoupling and enhancement in ROS production.
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2.2.1.3. Xanthine oxidase
This enzyme system provides an important endothelial source of superoxide in the vascular
wall [23, 26]. XO‐catalyzed reactions lead to oxygen reduction to produce superoxide from
purine metabolism. It has been reported that spontaneously hypertensive rats demonstrate
increased levels of both endothelial XO activity and ROS production, together with increased
arteriolar tone [21]. Furthermore, it was suggested that XO may contribute to end‐organ
damage in hypertension [27].
2.2.1.4. Mitochondrial dysfunction
The mitochondrion could behave as both a ROS source and target. Superoxide is produced in
the intermembrane space, but it is rapidly carried to the cytoplasm [28]. Either ubiquinol or
coenzyme Q could be a source of superoxide when these mitochondrial components are
partially reduced; but these molecules behave as antioxidants when they are fully reduced [29].
Superoxide produced by mammalian mitochondria in vitro mostly comes from complex I. This
high rate of complex I‐dependent superoxide production can be very effectively decreased
through mild uncoupling. In addition, it was found that patients with hypertension show
reduced activity of antioxidant enzymes [30].
2.2.2. Role of vascular wall components
In response to mechanical and hormonal stimuli, the endothelium releases agents participating
in the regulation of vasomotor tone. Particularly relevant is the ability of endothelium to exert
a protective role through the generation of vasorelaxing factors. In addition, pathophysiolog‐
ical conditions result in increased released of endothelium‐derived vasoconstricting factors,
such as ET‐1, AT‐II, UT‐II, superoxide anions, vasoconstrictor prostaglandins, and thrombox‐
ane A2, all of them capable of producing vasoconstrictor effects. It should be mentioned that
VSMC contribute to modulating blood pressure not solely in short‐term regulation of the blood
vessel diameter, but also in the structural remodeling occurring during long‐term adaptation,
both processes being mediated by ROS. It is of interest considering that the adventitia can also
participate in the development of hypertension, which is achieved through ROS contribution
in either reduction of NO bioavailability or vascular remodeling.
2.2.3. Role of vascular hormones and factors
2.2.3.1. Nitric oxide
NO plays a key role as a paracrine regulator of vascular tone. It is involved in the physiological
regulation responsible for the maintenance of the health of vascular endothelium through
processes such as inhibition of leukocyte‐endothelial cell adhesion, VSMC proliferation and
migration, and platelet aggregation. The effect of decreased NO bioavailability is particularly
relevant, leading to reduction of vasodilatory capacity in the vasculature, thereby providing
a mechanism of hypertension. The formation of NO from the substrates oxygen and L‐arginine
is catalyzed by the enzyme eNOS, being the predominant isoform of NOS family in the vascular
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wall. This enzyme can be rapidly activated by receptor‐mediated agonist stimulation, shear
stress, and allosteric modulators [31]. It is of interest to mention that NO diffuses easily to the
adjacent VSMC, thus binding to receptors such as soluble guanylyl cyclase. The numerous NO
biological properties include not only vasorelaxing and antiproliferative actions but also
antagonizing the effects of AT‐II, endothelins and ROS, among other vasoconstrictors. Though
L‐arginine, a substrate for eNOS, could be considered as a promising factor in preserving NO
formation, it failed to prevent blood pressure elevation and left ventricle remodeling in a model
based on chronic treatment with the methyl ester of N‐nitro‐L‐arginine (L‐NAME), an inhibitor
of eNOS [32]. Furthermore, NO‐deficient hypertension was completely prevented by the ACE
inhibitor captopril, yet without improving NOS activity. Another reported effect for NO
consists of its ability to exert an ACE downregulation effect. NO half‐life can be prolonged by
thiols, as these compounds protect NO from oxidation and are able to form nitrosothiols [33,
34]. It should be remarked that reduced NO levels can be the result of its combination with
superoxide to form peroxynitrite, a compound capable of enhancing oxidative stress by
oxidizing BH4, destabilizing eNOS, and producing more superoxide [22, 24, 25]. The impor‐
tance of the balance between NO and AT‐II in the regulation of the sympathetic tone has been
reported.
2.2.3.2. Renin‐angiotensin system
There is cumulated evidence supporting that the renin‐angiotensin system (RAS) contributes
to the development of cardiovascular disease. The production of AT‐II, a potent vasoactive
peptide, occurs in vascular beds having important ACE activity. Increased AT‐II production
above normal levels is able to induce vascular remodeling and endothelial dysfunction, as well
as increases in levels of blood pressure. At the cell level, AT‐II acts as a potent NOX activator,
thus leading to enhancement of ROS production [35, 36]. It was reported that the expression
of NOX subunits, oxidase activity, and ROS production are all increased in rat and mice models
of hypertension achieved by AT‐II infusion [37]. In addition, the effect of AT‐II is not only
confined to increasing NADPH oxidase activity but also upregulating SOD, likely as a
compensation mechanism against ROS increase. Consequently, ROS levels and oxidative
stress biomarkers may appear normal despite the occurrence of an oxidative challenge.
However, the consequences of oxidative stress will be apparent when ROS production
becomes overwhelming and the compensatory mechanisms are inadequate, thus explaining
the pathophysiological consequences [38]. Pharmacological inhibition of ACE by captopril and
enalapril prevented blood pressure rise in young spontaneously hypertensive rats. The
hypotensive effect of captopril is higher than that of enalapril, which could be due to the
antioxidant role of its thiol group [39]. Interestingly, NO not only antagonizes the vascular
effects of AT‐II on blood pressure, cell growth, and renal sodium excretion but also downre‐
gulates the synthesis of ACE and AT1 receptors. In addition, upregulation of eNOS expression
has been reported as a consequence of ACE inhibition [40]. Recently, a relationship through
Ca2+/calmodulin‐dependent protein kinase II has been proposed to link the actions of AT‐II
and ROS in cardiovascular pathological conditions [41].
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2.2.3.3. Acetylcholine
The endothelium‐dependent vasodilation by acetylcholine (Ach) in vascular vessels occurs
mainly via NO production. NO rapidly diffuses to the underlying VSMC, thereby inducing
relaxation in these cells. Under oxidative stress conditions, a diminution in NO bioavailability
should be expected, thus leading to significantly reduced ACh‐mediated vasodilation [40].
2.2.3.4. Endothelin‐1
Vascular endothelium, among others vascular tissues, produces potent vasoconstrictor
isopeptides known as endothelins. ET‐1 is the major endothelin generated by endothelial cells,
and is probably the most important in cardiovascular physiology and disease. It has been
demonstrated that large concentration of exogen ET‐1 acts as potent vasoconstrictor capable
of altering arterial pressure. ET‐1 mediates its effect through two receptors, ETA and ETB. ETA
exerts its effects via activation of NOX, XO, lipoxygenase, uncoupled NOS, and mitochondrial
respiratory chain enzymes. ETB induces relaxation on endothelial cells [42]. The vasocon‐
stricting action of ET‐1 is counteracted by vasodilators such as prostacyclin (PGI2) and/or NO,
and it has been seen that many factors that stimulate ET‐1 synthesis (e.g. thrombin, AT‐II) also
cause the release of the vasodilators above mentioned. Several studies reported in primary
hypertension demonstrate an increased ET‐1 vasoconstrictor tone, apparently dependent on
decreased endothelial ETB‐mediated NO production, contributing to NO bioavailability
impairment.
2.2.3.5. Urotensin‐II
UT‐II is the most potent vasoconstrictor identified [43]. It acts through the activation of NOX.
UT receptors have been identified in several other organs besides vascular bed, suggesting
that vasoconstriction is not its only effect [44, 45]. UT‐II has also been shown to act as a potent
vasodilator in some models [46]. Nevertheless, the role of UT‐II in disease is not fully elucidated
yet.
2.2.3.6. Norepinephrine
VSMC is innervated primarily by the sympathetic nervous system through three types of
adrenergic receptors: α1, α2 and β2. VSMC proliferation is stimulated by norepinephrine.
Interestingly, blood pressure is increased by over‐expression of inducible nitric oxide synthase
(iNOS) through central activation of the sympathetic nervous system, mainly mediated by an
increase in oxidative stress [5].
2.2.3.7. Prostaglandins
PGI2 is considered one of the most important vasodilators depending on the endothelium and
relaxes the vascular musculature. A large amount of substances that generate an increase in
PGI2 release have been described, such as thrombin, arachidonic acid, histamine, and seroto‐
nin. Prostaglandin H2 is formed by the prostaglandin H2 synthase, which uses arachidonic
acid as a substrate. Then, prostaglandin H2 is converted to PGI2, a vasoactive molecule.
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Oxidative stress‐related conditions, such as hypertension, impair the PGI2‐mediated vasodi‐
lation. It has been demonstrated that peroxynitrite inhibits the enzymatic activity of prosta‐
cyclin synthase. Thus, the isoform prostaglandin H2 synthase‐2 may mediate vascular
dysfunction under such conditions.
2.2.3.8. Homocysteine
It has been proposed that homocysteine plays an important role in the pathophysiology of
primary hypertension [3]. An increase in homocysteinemia augments the proliferation of
VSCM, thus altering the elasticity of vascular wall; it generates an oxidative stress state and
diminishes NO bioavailability, thus impairing vasodilation. All the mechanisms exposed
contribute to elevated blood pressure [47]. Homocysteine could also lead to endothelium
oxidative damage [3]. The administration of vitamins B6, B12, and folic acid has been proposed
as a potential adjuvant treatment in hypertension, probably by correcting the increased
homocysteinemia [3, 48]. Despite the above mentioned, further randomized controlled trials
are required to establish the efficacy of these therapeutic agents in the treatment of hyperten‐
sion.
A hypothesis for the role of vascular oxidative stress in hypertension is depicted in Figure 1.
Besides the key role of ROS production in the vasculature and its relation to hypertension, it
has been demonstrated that hypertensive stimuli, such as high salt and AT‐II, also increase the
production in the kidney and the central nervous system, contributing either to generate
hypertension or to the untoward sequels of this disease [49, 50]
Figure 1. Schematic summary of the role of vascular oxidative stress in the pathogenesis of hypertension. NO: nitric
oxide, eNOS: nitric oxide synthase, BH4: tetrahydrobiopterin, and mPTP: mitochondrial permeability transition pore.
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3. Antioxidants in hypertension
This section refers to the antihypertensive role of endogenous and exogenous antioxidants that
have demonstrated their ability to alter the blood vessels’ function and to participate in the
main redox reactions involved in the pathophysiology of hypertension.
3.1. Vitamin C
Vitamin C (or ascorbate) is a potent and widely used antioxidant, characteristically water‐
soluble. It has been described that this antioxidant could act as an enzyme modulator on the
vascular wall, upregulating eNOS and downregulating NOX [51]. An inverse relationship
between vitamin C plasma levels and arterial pressure in both healthy and hypertensive
population has been demonstrated in several studies [15]. Antioxidant supplementation
improves vascular function and reduces blood pressure in both experimental models [52, 53]
and in patients [54, 55]. Ascorbate may improve vasodilation, probably by increasing NO
bioavailability [56–58]. Vitamin C could protect BH4 from oxidation, which leads to an increase
in the enzymatic activity of eNOS.
Despite the rationale of using vitamin C as an antihypertensive molecule, several clinical trials
with methodological differences (including number of patients and follow‐up) have yielded
inconsistent outcomes [59–64]. The absence of antihypertensive effect observed in trials using
the administration of ascorbate could be due to the lack of consideration of its pharmacological
characteristics, mainly pharmacokinetics. It was determined in experimental conditions that
the antihypertensive effect of ascorbate is reachable at a plasma concentration of 10 mM [57].
This concentration allows ascorbate to efficiently compete against the reaction between NO
and superoxide, which is increased in oxidative stress–related conditions such as hyperten‐
sion. The plasma level mentioned earlier is not reachable through oral administration of
vitamin C. Daily oral doses of vitamin C between 60 and 100 mg are sufficient for the renal
ascorbate threshold to occur. Plasma is completely saturated at doses of 400 mg daily, leading
to a steady state level of 80 μM [65]. Therefore, it is plausible to propose that the antihyper‐
tensive effect of ascorbate would only be reachable with a high‐dose infusion.
3.2. Vitamin E
Vitamin E is a lipid‐soluble antioxidant which has received significant attention during the
last decades. An epidemiological association between high dietary vitamin E intake and a
lower incidence of cardiovascular disease has been established [58]. A growing body of
evidence indicates that vitamin E, besides its antioxidant properties, could act as a biological
modifier and is also capable of regulating mitochondrial generation of free radicals in a dose‐
dependent manner.
Interestingly, some studies fail to demonstrate the beneficial effects of vitamin E in cardiovas‐
cular disease patients [66–69]. Moreover, one trial proving vitamin E supplementation showed
an increase in blood pressure and cardiac frequency in type 2 diabetes patients [70]. Probably,
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vitamin E by itself is unlikely to achieve enough levels to counteract all components of
oxidative stress acting in primary hypertension [71].
3.3. Association of vitamins C and E
Alfa‐tocopheroxyl radical is reduced in vivo by ascorbate; therefore vitamin C may be needed
for achieving the beneficial effects of vitamin E [72]. In fact, both antioxidants may act
synergistically to generate appropriate conditions for NO synthesis in endothelium [73].
Therefore, the association between vitamins C and E provides a reinforcement of their
biological properties in a synergistic manner and could lead to a significant antihypertensive
effect; however, further studies are required [74].
Despite the fact that some short‐term studies have demonstrated that the supplementation of
both antioxidants reduces blood pressure [60, 63, 64, 75], long‐term clinical trials have failed
to support this hypothesis. However, most of these studies have some serious methodological
bias, mainly lack of rigorous exclusion criteria [76].
3.4. Allopurinol
XO has been proposed as an important enzymatic source of free radicals in the endothelium
[24]. It produces uric acid by catalyzing the two final steps of purine metabolism. It has been
demonstrated that XO activity is positively correlated with arteriolar tone and blood pressure
[77, 78]. Moreover, allopurinol, an XO inhibitor, is capable of improving endothelial function
in some experimental models. Treatment with allopurinol decreased blood pressure in a young
people‐based study [79], hypertensive murine models [80], and CKD patients [81]. Despite the
evidence supplied by small studies, a small number of randomized controlled trials have not
demonstrated benefit using XO inhibitors [82].
3.5. Selenium
Selenium is an essential trace element and a key part of several proteins. Its antioxidant
properties are carried out mainly by selenocysteine residues, which are an integral constituent
of glutathione peroxidase (GSH‐Px), thioredoxin reductases (TR), and selenoprotein P [83]. It
has been proposed that the maintenance of full GSH‐Px and TR activity by proper selenium
dietary intake could be useful for the prevention of cardiovascular disease. From a molecular
point of view, selenium is capable of preventing the activity of nuclear factor kappa B (NF‐κB)
[84], conferring selenium anti‐inflammatory and antioxidant properties. The inhibition of NF‐
kB is probably the result of the binding of selenium to the factor thiols [85].
Several trials have proved the antioxidant properties of selenium [84, 86–91]. Low‐dose
selenium showed to provide significant protection of coronary endothelium against oxidative
damage in humans [83]. In spontaneously hypertensive rats, selenium supplementation was
associated with an increased antioxidant response and protection against cardiac oxidative
injury, as well as a reduction in disease severity and mortality [92]. Besides, in hypertensive
pregnancies, reduced selenium levels are associated with a decrease in GSH‐Px activity [93].
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Therefore, it is plausible to propose that selenium deficiency could be an independent risk
factor of cardiovascular disease, including hypertension [94].
3.6. N‐acetylcysteine
N‐acetylcysteine (NAC) is a sulfhydryl group donor that holds great attention for its antioxi‐
dant properties and potential benefits in cardiovascular disease. In salt‐sensitive hypertension,
NAC is capable of improving renal dysfunction and decreasing blood pressure [95]. The
antihypertensive effect of NAC is mainly due to NO‐dependent mechanisms and is probably
mediated by the inhibition of oxidative stress [96]. NAC effectively prevents BH4 oxidation
by the increased superoxide present in primary hypertension [97]. Besides this, NAC can
protect against oxidative injury directly by scavenging ROS and inhibiting lipid peroxidation
[98, 99].
3.7. Polyphenols
Polyphenols have been defined as the most abundant antioxidants in human diet. They exert
several protective mechanisms, including ROS scavenging, iron chelating and modulation of
antioxidant enzymes [100, 101]. NAC also possibly increases the endothelium‐NO production
[102, 103]. In this regard, NO levels increase after the consumption of polyphenols by humans
[104]. Polyphenols improve endothelial function by increasing glutathione and inhibiting pro‐
oxidant enzymes such as NOX and XO [105]. Despite this, some studies using polyphenols
and antioxidant vitamins have shown an increase in blood pressure [106]. Therefore, the
evidence is still insufficient to establish polyphenols as a first‐line treatment in hypertension.
A summary of the antioxidant approaches as clinical interventions on essential hypertension
is presented in Table 1.
Details of study Results Reference
Intrabrachial vitamin C (2.4 mg/100 mL forearm
tissue per minute). Randomized, placebo‐
controlled trial
In hypertensive patients but not in control subjects,
vitamin C increased the impaired vasodilation to
acetylcholine
[107]
Intra‐arterial infusion of vitamin C at 24 mg/min
for 10 minutes. Randomized trial
Forearm blood flow response to acetylcholine was
significantly enhanced with intra‐arterial infusion of
vitamin C in hypertensive group before antihypertensive
treatment
[108]
Oral administration of 500, 1000, or 2000 mg of
vitamin C once daily. Randomized, double‐blind,
placebo‐controlled trial
Significant diminution of mean systolic blood pressure
and diastolic blood pressure, with no differences
between the increasing doses of vitamin C
[109]
Chronic supplementation of 600mg/daily of
vitamin C. Randomized, placebo‐controlled trial
Reduced systolic blood pressure and pulse pressure in
ambulatory elderly patients, but not in adult group
[110]
Included 29 trials of vitamin C supplementation.
Meta‐analysis
In short‐term trials, vitamin C supplementation reduces
systolic and diastolic blood pressure
[111]
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Details of study Results Reference
Oral supplementation: 1g vitamin C + 400 UI
vitamin E or placebo for 8 weeks. Randomized
double‐blind placebo‐controlled trial
Specific association between oxidative stress‐related
parameters and blood pressure. Patients with essential
hypertension had significantly lower systolic, diastolic,
and mean arterial blood pressure
[112]
ACE inhibitors + NAC (600 mg t.i.d.) or ACE
inhibitors only. Randomized, controlled trial,
crossover study
Significant decrease in systolic and diastolic blood
pressure with the combination of ACE inhibitors and
NAC compared to ACE inhibitors‐only
[113]
Intra‐arterial administration: NAC (48 g/min) or
vitamin C (18 mg/min). Cross‐over randomized
study
Intra‐arterial administration of NAC had no effect on
endothelium‐dependent vasodilation. Intra‐arterial
vitamin C improved endothelium‐dependent
vasodilation
[114]
Vitamin C supplement daily. Either 50 or 500 mg,
for 5 years. Randomized double‐blind controlled
trial
Neither systolic nor diastolic blood pressure was
significantly related with the serum vitamin C
concentration
[115]
Table 1. Clinical trials accounting for strategies using antioxidants in essential hypertension.
4. Conclusions and perspectives
There is a growing amount of evidence supporting the view that oxidative stress is involved
and plays a key role in the pathophysiology of primary hypertension. In this regard, ROS act
as mediators of the major physiological vasoconstrictors, increasing intracellular calcium
concentration. In this review, we propose an integrative view of how oxidative stress is
involved in the genesis of hypertension, mainly by reducing bioavailability of NO.
Antioxidant therapy can curtail the development of hypertension in animal models, but
remains controversial in humans. Possible confounding factors in patients include co‐existing
pathologies and treatments and lack of selection of treatments according to ROS levels, among
others. However, the dietary intake of antioxidants and polyphenols could have an effect on
the primary prevention or reduction of hypertension. Though existing molecular basis and in‐
vitro evidence support the use of diverse antioxidants, clinical evidence continues to be
controversial. It is necessary to perform basic/clinical trials that augment the current findings,
which could eventually help to elucidate the role of antioxidants as novel therapy for essential
hypertension. It is important to mention that the potential role of antioxidants in treatment of
hypertension probably is reachable only at early stages of the disease, when endothelial
dysfunction predominates over structural vascular damage.
In summary, oxidative stress plays a key role in the pathophysiology of hypertension, and
antioxidants appear to be a promising treatment or co‐adjuvant therapy, but further well‐
designed and conducted trials are required to establish them as a major alternative of phar‐
macology agents.
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